Search for: "Non-Hodgkin's Lymphoma"
CTI Receives Complete Response Letter from the FDA for Pixantrone NDA; CTI to File for Expanded Access for Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
HSMN NewsFeed,
9 Apr 2010:
Biopharmaceuticals, Oncology, FDA[Cell Therapeutics, Pixuvri, pixantrone dimaleate, non-Hodgkin's lymphoma]
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
HSMN NewsFeed,
19 Mar 2010:
Biopharmaceuticals, Oncology, Regulatory[Mundipharma, Levact, bendamustine, non-Hodgkin's lymphoma, leukemia, myeloma]
European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
HSMN NewsFeed,
21 Dec 2009:
Biopharmaceuticals, Oncology, Regulatory[Cell Therapeutics, pixantrone, orphan drug designation, non-Hodgkin's lymphoma]
Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
HSMN NewsFeed,
17 Dec 2009:
Biopharmaceuticals, Oncology[Cell Therapeutics, pixantrone, non-Hodgkin's lymphoma]
Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia at 51st American Society of Hematology Annual Meeting
HSMN NewsFeed,
7 Dec 2009:
Biopharmaceuticals, Drug Delivery, Oncology[Hana Biosciences, Marqibo, vincristine, liposomes, acute lymphoblastic leukemia]
Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma
HSMN NewsFeed,
5 Nov 2009:
Biopharmaceuticals, Oncology[Cephalon, TREANDA, bendamustine, non-Hodgkin's lymphoma]
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
HSMN NewsFeed,
3 Nov 2009:
Biopharmaceuticals, Oncology, Reimbursement[Spectrum Pharmaceuticals, ZEVALIN, ibritumomab tiuxetan, non-Hodgkin’s Lymphoma]
Cell Therapeutics Applies for European Orphan Drug Designation for Pixantrone in Aggressive Non-Hodgkin's Lymphoma (NHL)
HSMN NewsFeed,
29 Sep 2009:
Biopharmaceuticals, Oncology, Regulatory[Cell Therapeutics, pixantrone, Non-Hodgkin's Lymphoma]
FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma
HSMN NewsFeed,
2 Sep 2009:
Biopharmaceuticals, Oncology, FDA[Gloucester Pharmaceuticals, romidepsin, non-Hodgkin's lymphoma]
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
HSMN NewsFeed,
26 Aug 2009:
Biopharmaceuticals, Oncology[Genmab, Arzerra, ofatumumab, non-Hodgkin's lymphoma]
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
HSMN NewsFeed,
31 Jul 2009:
Biopharmaceuticals, Oncology, Personnel[Cephalon]
Genentech Announces Appointment of Sandra J. Horning, M.D., To Senior Vice President, Global Head, Clinical Development Hematology/Oncology
HSMN NewsFeed,
28 Jul 2009:
Biopharmaceuticals, Personnel[Genentech]
ChemGenex Appoints Mr. Thomas DeZao as Senior Vice President and Chief Commercial Officer
HSMN NewsFeed,
20 Jul 2009:
Biopharmaceuticals, Oncology, Personnel[ChemGenex Pharmaceuticals, omacetaxine, personalized medicine]
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
HSMN NewsFeed,
19 Jun 2009:
Biopharmaceuticals, Oncology[Cephalon, lestaurtinib, acute myelogenous leukemia]
Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non-Hodgkin's Lymphoma Patients
HSMN NewsFeed,
5 Jun 2009:
Biopharmaceuticals, Oncology[Helsinn Healthcare, palonosetron, Aloxi , Onicit, Paloxi]
Pixantrone Now Available in Europe on a Named-Patient Basis
HSMN NewsFeed,
5 May 2009:
Biopharmaceuticals, Oncology, Regulatory[Cell Therapeutics, pixantrone, non-Hodgkin's lymphoma]
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
HSMN NewsFeed,
22 Apr 2009:
Biopharmaceuticals, Oncology[Immunomedics, milatuzumab, CD74]
Provenance Biopharmaceuticals Corp. Announces License Agreement with Merck Serono for the Development and Commercialization of Novel Immunocytokine for the Treatment of Cancer
HSMN NewsFeed,
18 Mar 2009:
Biopharmaceuticals, Oncology, Licensing[Provenance Biopharmaceuticals, Merck Serono, Merck KGaA, DI-Leu16-IL2]
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
HSMN NewsFeed,
16 Mar 2009:
Biopharmaceuticals, Oncology, Acquisitions[Spectrum Pharmaceuticals, RIT Oncology, ZEVALIN, Non-Hodgkin's Lymphoma]
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
HSMN NewsFeed,
11 Mar 2009:
Biopharmaceuticals[Genentech, Biogen Idec, Rituxan, rituximab, lupus nephritis, lupus]
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
HSMN NewsFeed,
23 Feb 2009:
Biopharmaceuticals, Personnel[Micromet , blinatumomab]
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
HSMN NewsFeed,
23 Feb 2009:
Biopharmaceuticals, Oncology, Acquisitions[Spectrum Pharmaceuticals, Cell Therapeutics, RIT Oncology, ZEVALIN]
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
HSMN NewsFeed,
18 Feb 2009:
Biopharmaceuticals, Oncology[Cell Therapeutics, pixantrone, non-Hodgkin's lymphoma]
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
HSMN NewsFeed,
10 Feb 2009:
Biopharmaceuticals, Oncology, Regulatory[Cell Therapeutics, pixantrone, non-Hodgkin's lymphoma]
Immunomedics Reports Properties and Structure-Function Relationships of Veltuzumab
HSMN NewsFeed,
29 Jan 2009:
Biopharmaceuticals, Oncology[Immunomedics, veltuzumab, lymphoma]
Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
HSMN NewsFeed,
27 Jan 2009:
Biopharmaceuticals, Oncology, FDA[Cell Therapeutics, pixantrone, non-Hodgkin's lymphoma]
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
HSMN NewsFeed,
22 Jan 2009:
Biopharmaceuticals, Oncology[Cell Therapeutics, Zevalin, ibritumomab tiuxetan, ocular adnexal lymphoma]
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
HSMN NewsFeed,
16 Dec 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, Spectrum Pharmaceuticals, RIT Oncology, Zevalin]
FDA Approves Genzyme's Mozobil
HSMN NewsFeed,
15 Dec 2008:
Biopharmaceuticals, FDA[Genzyme, Mozobil, plerixafor]
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
HSMN NewsFeed,
9 Dec 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, Zevalin]
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
HSMN NewsFeed,
6 Dec 2008:
Biopharmaceuticals, Oncology[Genentech, Biogen Idec, Rituxan, rituximab, chronic lymphocytic leukemia]
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
HSMN NewsFeed,
1 Dec 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, Spectrum Pharmaceuticals, Zevalin]
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
HSMN NewsFeed,
11 Nov 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, EXTEND trial, pixantrone, non-Hodgkin's lymphoma]
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
HSMN NewsFeed,
3 Nov 2008:
Biopharmaceuticals, Oncology, FDA[Cephalon, TREANDA, bendamustine, Indolent NHL, non-Hodgkin's lymphoma]
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
HSMN NewsFeed,
20 Oct 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, Zevalin, non-Hodgkin's lymphoma, Ibritumomab Tiuxetan]
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
HSMN NewsFeed,
5 Sep 2008:
Biopharmaceuticals, Oncology, FDA[TopoTarget, belinostat, Peripheral T-Cell Lymphoma]
Craig W. Philips Takes Helm at CTI
HSMN NewsFeed,
5 Aug 2008:
Biopharmaceuticals, Personnel[Cell Therapeutics]
Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
HSMN NewsFeed,
31 Jul 2008:
Biopharmaceuticals, Oncology[Genmab, GlaxoSmithKline, ofatumumab, HuMax-CD20, chronic lymphocytic leukemia]
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
HSMN NewsFeed,
14 Jul 2008:
Biopharmaceuticals, Oncology, Licensing[Immunomedics, Nycomed, veltuzumab]
Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
HSMN NewsFeed,
14 Jul 2008:
Biopharmaceuticals, Regulatory[Hana Biosciences, orphan drug designation, Marqibo]
Hana Biosciences Receives U.S. Orphan Drug Designation for Marqibo for the Treatment of Metastatic Uveal Melanoma
HSMN NewsFeed,
30 Jun 2008:
Biopharmaceuticals, Oncology, FDA[Hana Biosciences, Marqibo, vincristine, OPTISOME, metastatic uveal melanoma]
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
HSMN NewsFeed,
18 Jun 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, Bayer Schering Pharma, Zevalin]
Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
HSMN NewsFeed,
11 Jun 2008:
Biopharmaceuticals, Oncology[Biovest International, Accentia Biopharmaceuticals, BiovaxID]
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
HSMN NewsFeed,
9 Jun 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, Zevalin, Ibritumomab Tiuxetan, rituximab, lymphoma]
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
HSMN NewsFeed,
31 May 2008:
Biopharmaceuticals, Oncology[Wyeth, TORISEL, temsirolimus, non-Hodgkin's lymphoma]
Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
HSMN NewsFeed,
27 May 2008:
Biopharmaceuticals, Oncology[Favrille, Specifid, Rituxan, non-Hodgkin's lymphoma]
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
HSMN NewsFeed,
19 May 2008:
Biopharmaceuticals[Biogen Idec]
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
HSMN NewsFeed,
29 Apr 2008:
Biopharmaceuticals[Genentech, Rituxan, rituximab, systemic lupus erythematosus]
Veteran Drug Industry Executive to Become President of CTI
HSMN NewsFeed,
24 Apr 2008:
Biopharmaceuticals, Personnel[Cell Therapeutics, Craig Philips]
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
HSMN NewsFeed,
22 Apr 2008:
Biopharmaceuticals, Oncology[NCCN, Non-Hodgkin’s Lymphoma, bendamustine, rituximab, Rituxan, Genentech]
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV(TM)
HSMN NewsFeed,
17 Apr 2008:
Biopharmaceuticals, FDA[Dynavax Technologies, Merck, HEPLISAV, vaccine, hepatitis B]
Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma
HSMN NewsFeed,
17 Apr 2008:
Biopharmaceuticals, Oncology[Accentia Biopharmaceuticals, Biovest International, BiovaxID, cancer vaccine]
Biovest Reports that Independent Data Monitoring Committee Recommends Unblinding of Phase 3 Clinical Results for its Anti-Cancer Vaccine, BiovaxID(R)
HSMN NewsFeed,
17 Apr 2008:
Biopharmaceuticals, Oncology[Biovest International, Accentia Biopharmaceuticals, BiovaxID, cancer vaccine]
Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development
HSMN NewsFeed,
25 Mar 2008:
Biopharmaceuticals, Personnel[Micromet , BiTE antibodies]
Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
HSMN NewsFeed,
25 Mar 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, pixantrone, BBR2278, B cell, non-Hodgkin's lymphoma]
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
HSMN NewsFeed,
20 Mar 2008:
Biopharmaceuticals, Oncology[Immunomedics, SN-38, pancreatic cancer, colon cancer, lung cancer]
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
HSMN NewsFeed,
20 Mar 2008:
Biopharmaceuticals, Oncology, FDA[Cephalon, TREANDA, bendamustine, chronic lymphocytic leukemia]
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
HSMN NewsFeed,
18 Mar 2008:
Biopharmaceuticals, Oncology, FDA[Immunomedics, orphan drug designation, milatuzumab, multiple myeloma]
Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
HSMN NewsFeed,
17 Mar 2008:
Biopharmaceuticals[Dynavax Technologies, Merck, HEPLISAV, hepatitis B]
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
HSMN NewsFeed,
17 Mar 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, fludarabine, mitoxantrone, Zevalin, Ibritumomab, NHL]
Kiadis Pharma Obtains FDA Approval to Start a Phase III Clinical Trial for Reviroc(TM) in the United States
HSMN NewsFeed,
22 Feb 2008:
Biopharmaceuticals, Oncology[Kiadis Pharma, Reviroc]
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
HSMN NewsFeed,
20 Feb 2008:
Biopharmaceuticals, Oncology[Millennium Pharmaceuticals, VELCADE, bendamustine, rituximab, lymphoma]
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
HSMN NewsFeed,
19 Feb 2008:
Biopharmaceuticals, Oncology[Cephalon, TREANDA, bendamustine, B-cell, non-Hodgkin's lymphoma]
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
HSMN NewsFeed,
12 Feb 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, Zevalin, Ibritumomab Tiuxetan, non-Hodgkin's lymphoma]
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
HSMN NewsFeed,
25 Jan 2008:
Biopharmaceuticals[Genentech, Biogen Idec, Rituxan, rituximab, rheumatoid arthritis]
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
HSMN NewsFeed,
17 Jan 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, Zevalin, Ibritumomab Tiuxetan, Non-Hodgkin's Lymphoma]
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
HSMN NewsFeed,
31 Dec 2007:
Biopharmaceuticals, Oncology, FDA[Cephalon, TREANDA, bendamustine, non-Hodgkin's lymphoma]
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
HSMN NewsFeed,
27 Dec 2007:
Biopharmaceuticals, Acquisitions[Cell Therapeutics, Biogen Idec, Zevalin, ibritumomab tiuxetan]
Micromet Announces Changes in Management Team
HSMN NewsFeed,
14 Dec 2007:
Biopharmaceuticals, Personnel[Micromet , Christopher Schnittker]
Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma
HSMN NewsFeed,
10 Dec 2007:
Biopharmaceuticals, Oncology[Immunomedics, epratuzumab, non-Hodgkin's lymphoma, rituximab]
Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
HSMN NewsFeed,
6 Dec 2007:
Biopharmaceuticals, Oncology[Favrille, Specifid, FavId]
Marketing Application for Vorinostat Filed in Europe for the Treatment of Advanced, Refractory Cutaneous T-Cell Lymphoma
HSMN NewsFeed,
26 Nov 2007:
Biopharmaceuticals, Oncology, Regulatory[Merck, vorinostat, ZOLINZA, cutaneous T-cell lymphoma]
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
HSMN NewsFeed,
26 Nov 2007:
Biopharmaceuticals, Oncology[Millennium Pharmaceuticals, VELCADE, multiple myeloma, non-Hodgkin's lymphoma]
Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
HSMN NewsFeed,
1 Nov 2007:
Biopharmaceuticals[Dynavax Technologies, Merck, hepatitis B , HEPLISAV]
Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma
HSMN NewsFeed,
23 Oct 2007:
Biopharmaceuticals, Oncology[Cephalon, TREANDA, bendamustine, non-Hodgkin's lymphoma]
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
HSMN NewsFeed,
16 Oct 2007:
Biopharmaceuticals, Oncology[Biovest International, Accentia Biopharma, BiovaxID, Non-Hodgkin's Lymphoma]
Accentia Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis
HSMN NewsFeed,
8 Oct 2007:
Biopharmaceuticals, Neurology[Accentia Biopharmaceuticals, Revimmune, Multiple Sclerosis]
Accentia Biopharmaceuticals Announces Completion of Enrollment in Fast-Tracked Pivotal Phase 3 Clinical Trial of SinuNase for Chronic Sinusitis
HSMN NewsFeed,
8 Oct 2007:
Biopharmaceuticals[Accentia Biopharmaceuticals, SinuNase, Sinusitis]
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
HSMN NewsFeed,
21 Sep 2007:
Biopharmaceuticals, Oncology[Cephalon, TREANDA, bendamustine, chronic lymphocytic leukemia]
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
HSMN NewsFeed,
19 Sep 2007:
Biopharmaceuticals[Dynavax Technologies, HEPLISAV, hepatitis B]
Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer
HSMN NewsFeed,
12 Sep 2007:
Biopharmaceuticals, Personnel[Micromet]
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
HSMN NewsFeed,
12 Sep 2007:
Biopharmaceuticals, Oncology[Cell Therapeutics, PIX303, pixantrone, non-Hodgkin's lymphoma]
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
HSMN NewsFeed,
4 Sep 2007:
Biopharmaceuticals, Oncology[Roche Group, Tarceva, erlotinib, non-small cell lung cancer]
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
HSMN NewsFeed,
29 Aug 2007:
Biopharmaceuticals, Oncology, FDA[Cephalon, orphan drug designation, TREANDA, bendamustine, CLL]
Hana Biosciences Receives Fast Track Designation for Marqibo for the Treatment of Relapsed Acute Lymphoblastic Leukemia
HSMN NewsFeed,
22 Aug 2007:
Biopharmaceuticals, Oncology, FDA[Hana Biosciences, Marqibo, vincristine, OPTISOME, fast track designation]
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
HSMN NewsFeed,
16 Aug 2007:
Biopharmaceuticals, Acquisitions, Oncology[Cell Therapeutics, Biogen Idec, Zevalin, ibritumomab tiuxetan, NHL]
Accentia Biopharmaceuticals Updates Interim Analysis of Blinded Clinical Results in the Fast-Tracked Pivotal Phase 3 Trial of SinuNase for the Treatment of Refractory Chronic Sinusitis
HSMN NewsFeed,
15 Aug 2007:
Biopharmaceuticals[Accentia Biopharmaceuticals, SinuNase, sinusitis, intranasal amphotericin B]
Immunomedics Appoints Edward T. Wolynic to Board Of Directors
HSMN NewsFeed,
6 Aug 2007:
Biopharmaceuticals, Personnel[Immunomedics]
Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease
HSMN NewsFeed,
1 Aug 2007:
Biopharmaceuticals, Drug Delivery, FDA[Genta , Emisphere Technologies, G4544, Ganite, gallium nitrate, hypercalcemia]
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
HSMN NewsFeed,
31 Jul 2007:
Biopharmaceuticals, Neurology, FDA[Accentia Biopharmaceuticals, Revimmune, Multiple Sclerosis]
Journal of Clinical Oncology Publishes Data on ZOLINZA(TM) (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
HSMN NewsFeed,
20 Jul 2007:
Biopharmaceuticals, Oncology[Merck, T-cell lymphoma, ZOLINZA, vorinostat]
Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin's Lymphoma Meets Primary Endpoint
HSMN NewsFeed,
19 Jul 2007:
Biopharmaceuticals, Oncology[Genzyme, Mozobil, plerixafor, non-Hodgkin's lymphoma]
Micromet Promotes Carsten Reinhardt to Chief Medical Officer
HSMN NewsFeed,
19 Jul 2007:
Biopharmaceuticals, Personnel[Micromet , non-Hodgkin's lymphoma]
Cephalon Announces Plans for New NDA Filing for TREANDA(R)
HSMN NewsFeed,
28 Jun 2007:
Biopharmaceuticals, Oncology, FDA[Cephalon, TREANDA, bendamustine, chronic lymphocytic leukemia]
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
HSMN NewsFeed,
20 Jun 2007:
Biopharmaceuticals, Oncology[NCCN, vorinostat, alemtuzumab, gemcitabine, Non-Hodgkin's Lymphoma]
Cytokinetics Announces Second Extension of Research Term Under Collaboration With GlaxoSmithKline
HSMN NewsFeed,
19 Jun 2007:
Biopharmaceuticals, Oncology[Cytokinetics, GlaxoSmithKline, centromere-associated protein]
Genmab Announces Development Plans for Ofatumumab
HSMN NewsFeed,
18 Jun 2007:
Biopharmaceuticals, Oncology[Genmab, ofatumumab, HuMax-CD20, GlaxoSmithKline]
"The Group Room(R)" Cancer Talk Radio Show to Broadcast Follow-up Special to the 12th Congress of the European Hematology Association (EHA)
HSMN NewsFeed,
13 Jun 2007:
Oncology[Vital Options, The Group Room]
Latest Data Show MabThera(R) Provides Significant and Sustained Relief From Signs and Symptoms of Rheumatoid Arthritis
HSMN NewsFeed,
13 Jun 2007:
Biopharmaceuticals[Roche Group, rituximab, rheumatoid arthritis, MabThera]
Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe
HSMN NewsFeed,
11 Jun 2007:
Biopharmaceuticals, Oncology[Favrille, FavId, non-Hodgkin's lymphoma]
Biovest to File for Accelerated Conditional Approval of BiovaxID
HSMN NewsFeed,
5 Jun 2007:
Biopharmaceuticals, Oncology, FDA[Biovest, Accentia Biopharmaceuticals, BiovaxID, Non-Hodgkin's Lymphoma]
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Oncology[GlaxoSmithKline, BEXXAR, Tositumomab, 131I, non-Hodgkin's lymphoma]
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Oncology[Cytokinetics, Ispinesib, SB-743921, kinesin spindle protein, GlaxoSmithKline]
Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Oncology[Immunomedics, 131I, labetuzumab, Radioimmunotherapy, Colorectal Cancer]
Phase 2 Clinical Results of Ganite(R) Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Oncology[Genta , Ganite, gallium nitrate, non-Hodgkin's lymphoma]
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Oncology[Immunomedics, epratuzumab, acute lymphoblastic leukemia]
Final Data from a Phase 2 Trial Presented at ASCO Specifies Dose-dependent Activity of Adecatumumab (MT201)
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Oncology[Micromet , adecatumumab, Merck Serono, Merck KGaA, breast cancer]
Favrille Reports Status of Phase 2 Clinical Trial of FavId With Maintenance Rituxan for Indolent B-Cell Non-Hodgkin's Lymphoma
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Oncology[Favrille, FavId, Rituxan, B-cell non-Hodgkin's lymphoma]
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
HSMN NewsFeed,
3 Jun 2007:
Biopharmaceuticals, Oncology[Biogen Idec, Zevalin, Ibritumomab tiuxetan, radioimmunotherapy, lymphoma]
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
HSMN NewsFeed,
3 Jun 2007:
Biopharmaceuticals, Oncology[Genentech, Pertuzumab, Trastuzumab-DM1, Apomab, Apo2L/TRAIL]
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
HSMN NewsFeed,
3 Jun 2007:
Biopharmaceuticals, Oncology[Millennium Pharmaceuticals, VELCADE, bortezomib, Non-Hodgkin's Lymphoma]
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
HSMN NewsFeed,
30 May 2007:
Biopharmaceuticals, Oncology, FDA[Wyeth Pharmaceuticals, TORISEL, temsirolimus, renal cell carcinoma]
Genitope Corporation Initiates Clinical Trial to Evaluate Use of MyVax(R) Personalized Immunotherapy Following Treatment With Rituximab and Chemotherapy for Follicular Non-Hodgkin's Lymphoma
HSMN NewsFeed,
21 May 2007:
Biopharmaceuticals, Oncology[Genitope, MyVax, rituximab, follicular non-Hodgkin's lymphoma]
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
HSMN NewsFeed,
21 May 2007:
Biopharmaceuticals, Drug Delivery, Oncology, FDA[Ortho Biotech, DOXIL, doxorubicin, VELCADE, bortezomib, multiple myeloma]
Cell Therapeutics, Inc. Receives FDA Special Protocol Assessment (SPA) Comments on the Design of Phase III Trial of Pixantrone in Relapsed Indolent NHL
HSMN NewsFeed,
17 May 2007:
Biopharmaceuticals, Oncology, FDA[Cell Therapeutics, non-Hodgkin's lymphoma, Pixantrone, fast track designation]
Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
HSMN NewsFeed,
16 May 2007:
Biopharmaceuticals, Oncology, FDA[Gloucester Pharmaceuticals, romidepsin, histone deacetylase, T-cell lymphoma]
Accentia Biopharmaceuticals Makes Milestone Payment Based on Fast Tracked Pivotal Phase 3 Study with SinuNase for the Treatment of Chronic Sinusitis
HSMN NewsFeed,
14 May 2007:
Biopharmaceuticals[Accentia Biopharmaceuticals, SinuNase, amphotericin B, chronic sinusitis]
Favrille Appoints Richard Ghalie, M.D., Chief Medical Officer
HSMN NewsFeed,
8 May 2007:
Biopharmaceuticals, Oncology, Personnel[Favrille]
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
HSMN NewsFeed,
7 May 2007:
Biopharmaceuticals, FDA[Cell Therapeutics, fast track designation, pixantrone, non-Hodgkin's lymphoma]
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
HSMN NewsFeed,
1 May 2007:
Biopharmaceuticals, Neurology[Genentech, Biogen Idec, Rituxan, rituximab, multiple sclerosis]
Dr Reddy's launches Reditux(TM) - Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma
HSMN NewsFeed,
30 Apr 2007:
Biopharmaceuticals, Oncology[Dr Reddy's Laboratories, Reditux, rituximab, monoclonal antibody]
Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission
HSMN NewsFeed,
19 Apr 2007:
Biopharmacetuicals, Oncology, Regulatory[Allos Therapeutics, orphan drug designation, pralatrexate, T-cell lymphoma]
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection
HSMN NewsFeed,
17 Apr 2007:
Biopharmaceuticals, Oncology[Millennium Pharmaceuticals, VELCADE, multiple myeloma]
Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting
HSMN NewsFeed,
15 Apr 2007:
Biopharmaceuticals, Oncology[Eli Lilly, ALIMTA, pemetrexed, GEMZAR, gemcitabine, enzastaurin]
Enzastaurin Granted Orphan Drug Status for Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
HSMN NewsFeed,
26 Mar 2007:
Biopharmaceuticals, Oncology, Regulatory[Eli Lilly, enzastaurin, non-Hodgkin's lymphoma]
EpiCept Corporation Appoints Stephane Allard, M.D. as New Chief Medical Officer
HSMN NewsFeed,
26 Mar 2007:
Biopharmaceuticals, Personnel[EpiCept]
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
HSMN NewsFeed,
13 Mar 2007:
Biopharmaceuticals, Oncology, FDA[Cell Therapeutics, pixantrone, Non-Hodgkin's Lymphoma]
Genta and IDIS Announce Global Ex-U.S. Agreement for Named Patient/Compassionate Use Distribution of Ganite(R) and Genasense(R)
HSMN NewsFeed,
7 Mar 2007:
Biopharmaceuticals[Genta Inc, IDIS , Ganite, gallium nitrate, Genasense, oblimersen]
Dynavax Reports Interim, One-Year Data From Ragweed Allergy Trial at AAAAI
HSMN NewsFeed,
23 Feb 2007:
Biopharmaceuticals[Dynavax Technologies, TOLAMBA]
Althea Technologies Announces the Development of a Diagnostic Capable of Differentiating Multiple Forms of Childhood Cancer
HSMN NewsFeed,
20 Feb 2007:
Diagnostics, Oncology[Althea Technologies]
Favrille Announces Agreement With Berlex, Inc. Regarding Use of FavId(R) in Combination With Leukine(R) (sargramostim) in B-Cell Non-Hodgkin's Lymphoma
HSMN NewsFeed,
14 Feb 2007:
Biopharmaceuticals, Oncology[Favrille, Berlex, FavId, Leukine, non-Hodgkin's lymphoma]
Favrille Announces Long-Term Follow-Up Data From Phase 2 Clinical Trial of FavId Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin's Lymphoma
HSMN NewsFeed,
12 Feb 2007:
Biopharmaceuticals, Oncology[Favrille, FavId, non-Hodgkin's lymphoma]
Gloucester Pharmaceuticals Receives Special Protocol Assessment for Pivotal Phase II Trial of Romidepsin in Patients with Peripheral T-Cell Lymphoma
HSMN NewsFeed,
30 Jan 2007:
Biopharmaceuticals, Oncology, FDA[Gloucester Pharmaceuticals, romidepsin, T-cell lymphoma]
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
HSMN NewsFeed,
25 Jan 2007:
Biopharmaceuticals, Oncology[Biogen Idec, galiximab, Non-Hodgkin's Lymphoma]
Cytokinetics Announces Changes to its Executive Management Team and Board of Directors
HSMN NewsFeed,
22 Jan 2007:
Biopharmaceuticals, Personnel[Cytokinetics]
Hana Biosciences Receives Orphan Drug Designation for Marqibo(R) (Vincristine Sulfate Liposomes Injection) for the Treatment of Acute Lymphoblastic Leukemia
HSMN NewsFeed,
16 Jan 2007:
Biopharmaceuticals, Oncology, FDA[Hana Biosciences, orphan drug designation, Marqibo, acute lymphoblastic leukemia]
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) With FDA for XYOTAX Lung Cancer Trial in Women
HSMN NewsFeed,
10 Jan 2007:
Biopharmaceuticals, Oncology[Cell Therapeutics, XYOTAX, PGT306, lung cancer]
GlaxoSmithKline Commences Tender Offer to Acquire PRAECIS PHARMACEUTICALS
HSMN NewsFeed,
9 Jan 2007:
Biopharmaceuticals, Mergers & Acquisitions[GlaxoSmithKline, PRAECIS PHARMACEUTICALS]
Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40
HSMN NewsFeed,
8 Jan 2007:
Biopharmaceuticals, Oncology, Licensing[Seattle Genetics, Genentech, SGN-40]
Seattle Genetics and Agensys Announce Collaboration to Co-Develop and Commercialize Antibody-Drug Conjugate Therapies for Cancer
HSMN NewsFeed,
8 Jan 2007:
Biopharmaceuticals, Licensing[Seattle Genetics, Agensys]
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in Patients With Peripheral T-cell Lymphoma
HSMN NewsFeed,
8 Jan 2007:
Biopharmaceuticals, Oncology[Allos Therapeutics, PROPEL trial, PDX, pralatrexate]
CoGenesys Files to Begin Clinical Trials of Neugranin for the Prevention of Infections in Cancer Patients
HSMN NewsFeed,
3 Jan 2007:
Biopharmaceuticals[CoGenesys, Neugranin]
Accentia Biopharmaceuticals in Discussions with Pharmaceutical Companies on SinuNase Partnership
HSMN NewsFeed,
21 Dec 2006:
Biopharmaceuticals[Accentia Biopharmaceuticals, SinuNase, amphotericin B, chronic sinusitis]
GlaxoSmithKline to Acquire PRAECIS PHARMACEUTICALS
HSMN NewsFeed,
21 Dec 2006:
Biopharmaceuticals, Mergers & Acquisitions[PRAECIS PHARMACEUTICALS, GlaxoSmithKline]
Data Monitoring Committee Recommends Closing Enrollment in Recurrent Glioblastoma Study
HSMN NewsFeed,
21 Dec 2006:
Biopharmaceuticals, Oncology[Eli Lilly, Enzastaurin, Glioblastoma, STEERING trial]
Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM), Hepatitis B Vaccine
HSMN NewsFeed,
20 Dec 2006:
Biopharmaceuticals[Dynavax Technologies, HEPLISAV, hepatitis B, PHAST, Engerix-B]
Hana Biosciences Announces Filing of a Special Protocol Assessment (SPA) for Marqibo(R) (Vincristine Sulfate Liposomes Injection) in Relapsed Acute Lymphoblastic Leukemia
HSMN NewsFeed,
20 Dec 2006:
Biopharmaceuticals, Oncology[Hana Biosciences, Marqibo, vincristine, acute lymphoblastic leukemia]
GlaxoSmithKline and Genmab Enter Global Agreement For HuMax-CD20
HSMN NewsFeed,
19 Dec 2006:
Biopharmaceuticals, Oncology[Genmab, GlaxoSmithKline, HuMax- CD20, ofatumumab, B-CLL, non-Hodgkin's lymphoma]
CuraGen and TopoTarget Announce Expansion of Belinostat (PXD101) Clinical Trial in Cutaneous T-cell Lymphoma (CTCL)
HSMN NewsFeed,
14 Dec 2006:
Biopharmaceuticals, Oncology[CuraGen, TopoTarget, belinostat, Cutaneous T-cell Lymphoma]
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for Peripheral T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
HSMN NewsFeed,
12 Dec 2006:
Biopharmaceuticals, Oncology[Gloucester Pharmaceuticals, romidepsin, depsipeptide, peripheral T-cell lymphoma]
Gloucester Pharmaceuticals Reports Clinically Significant Responses in Interim Analysis of Pivotal Trial for Cutaneous T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
HSMN NewsFeed,
12 Dec 2006:
Biopharmaceuticals, Oncology[Gloucester Pharmaceuticals, romidepsin, depsipeptide, cutaneous T-cell lymphoma]
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
HSMN NewsFeed,
12 Dec 2006:
Biopharmaceuticals, Oncology[Cell Therapeutics, pixantrone, CPOP combination]
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
HSMN NewsFeed,
11 Dec 2006:
Biopharmaceuticals, Oncology[Millennium Pharmaceuticals, VELCADE, bortezomib, lymphoma]
'Impressive' Complete Remission and 'Durable' Survival Data in Relapsed Indolent NHL Patients Identifies New Potential Registration Trial for Pixantrone
HSMN NewsFeed,
11 Dec 2006:
Biopharmaceuticals, Oncology[Cell Therapeutics, non-Hodgkin's lymphoma, pixantrone]
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
HSMN NewsFeed,
8 Dec 2006:
Biopharmaceuticals, Oncology, FDA[Millennium Pharmaceuticals, VELCADE, bortezomib, Non-Hodgkin's Lymphoma]
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
HSMN NewsFeed,
8 Dec 2006:
Biopharmaceuticals, Oncology[Celgene, REVLIMID, lenalidomide, multiple myeloma, lymphoma, leukemia]
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
HSMN NewsFeed,
4 Dec 2006:
Biopharmaceuticals, Oncology[Millennium Pharmaceuticals, VELCADE, Bortezomib, multiple myeloma, lymphoma]
Study Showed Epratuzumab in Combination with Rituximab and Chemotherapy is Safe, Tolerable, and Active in Aggressive Lymphoma
HSMN NewsFeed,
4 Dec 2006:
Biopharmaceuticals, Oncology[Immunomedics, epratuzumab, rituximab, B-cell lymphoma, lymphoma]
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in Phase 3 Trial
HSMN NewsFeed,
28 Nov 2006:
Biopharmaceuticals[Dynavax Technologies, HEPLISAV, hepatitis B]
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
HSMN NewsFeed,
27 Nov 2006:
Biopharmaceuticals, Oncology, Licensing[Cytokinetics, GlaxoSmithKline, kinesin spindle protein, ispinesib]
Epratuzumab and Rituximab Have Different Modes of Action
HSMN NewsFeed,
13 Nov 2006:
Biopharmaceuticals[Immunomedics, epratuzumab, rituximab]
Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
HSMN NewsFeed,
13 Nov 2006:
Biopharmaceuticals, Oncology[Favrille, FavId, non-Hodgkin's lymphoma]
Genzyme Completes Tender Offer for Outstanding Shares of AnorMED
HSMN NewsFeed,
7 Nov 2006:
Biopharmaceuticals, Mergers & Acquisitions[Genzyme, AnorMED]
Cytokinetics Announces Presentations Relating to Clinical Trial Data on CK-1827452 and its Cardiac Myosin Activator Program at the 2006 Annual American Heart Association Scientific Sessions Meeting
HSMN NewsFeed,
6 Nov 2006:
Biopharmaceuticals, Cardiology[Cytokinetics, CK-1827452, heart failure]
Accentia Biopharmaceuticals Commences Fast-Tracked Phase 3 Clinical Trial of SinuNase for the Treatment of Chronic Sinusitis
HSMN NewsFeed,
6 Nov 2006:
Biopharmaceuticals, Personnel[Accentia Biopharmaceuticals, SinuNase, chronic sinusitis]
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
HSMN NewsFeed,
31 Oct 2006:
Biopharmaceuticals, Oncology[Berlex, Berlex Laboratories, Schering AG, non-Hodgkin's lymphoma]
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
HSMN NewsFeed,
26 Oct 2006:
Biopharmaceuticals, Oncology[Millennium Pharmaceuticals, Ortho Biotech, VELCADE, multiple myeloma]
ProNAi Closes Successful Bridge Funding Round, Secures $6.65 Million Total
HSMN NewsFeed,
24 Oct 2006:
Biopharmaceuticals, Oncology, Venture Capital[ProNAi Therapeutics, DNA interference]
New Landmark Study Shows the Use of a BiovaxID Formulation Improves Disease Free survival in 80% of Patients Whose Cancer has Relapsed after Chemotherapy Administered With or Without Rituxan
HSMN NewsFeed,
19 Oct 2006:
Biopharmaceuticals, Oncology[Accentia Biopharmaceuticals, BiovaxID, Idiotype vaccine, Non-Hodgkins Lymphoma]
Genzyme and AnorMED Reach Agreement on Acquisition
HSMN NewsFeed,
17 Oct 2006:
Biopharmaceuticals, Mergers & Acquisitions[Genzyme, AnorMED, MOZOBIL, stem cell]
Favrille Appoints Former Eli Lilly Executive Michael Eagle Chairman of the Board
HSMN NewsFeed,
12 Oct 2006:
Biopharmaceuticals, Personnel[Favrille]
Micromet, Inc. Expands Management and Appoints Christopher P. Schnittker as Senior Vice President and Chief Financial Officer
HSMN NewsFeed,
12 Oct 2006:
Biopharmaceuticals, Personnel[Micromet]
Genzyme Announces Proposal to Increase Its Offer to Acquire AnorMED to $13.50 Per Share in Cash
HSMN NewsFeed,
10 Oct 2006:
Biopharmaceuticals, Mergers & Acquisitions[Genzyme, AnorMED]
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
HSMN NewsFeed,
9 Oct 2006:
Biopharmaceuticals, Oncology, FDA[Merck, ZOLINZA, vorinostat, cutaneous T-cell lymphoma]
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
HSMN NewsFeed,
6 Oct 2006:
Biopharmaceuticals, Oncology, FDA[Merck, ZOLINZA, vorinostat, cutaneous T-cell lymphoma, non-Hodgkin's lymphoma]
Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
HSMN NewsFeed,
6 Oct 2006:
Biopharmaceuticals, Oncology[Millennium Pharmaceuticals, VELCADE, Bortezomib, Mantle Cell Lymphoma]
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
HSMN NewsFeed,
4 Oct 2006:
Biopharmaceuticals, Oncology[Biogen Idec, Schering AG, Zevalin, Ibritumomab Tiuxetan, ZEAL trial]
NEW ENGLAND JOURNAL OF MEDICINE Reports Positive Results From Dynavax' Ragweed Allergy Therapy Trial
HSMN NewsFeed,
4 Oct 2006:
Biopharmaceuticals[Dynavax Technologies, Allergic Rhinitis, TOLAMBA]
Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma
HSMN NewsFeed,
3 Oct 2006:
Biopharmaceuticals, Oncology, FDA[Allos Therapeutics, fast track designation, PDX, pralatrexate, T-cell lymphoma]
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
HSMN NewsFeed,
2 Oct 2006:
Biopharmaceuticals, Oncology[Celgene, REVLIMID, lenalidomide, non-Hodgkins lymphoma]
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
HSMN NewsFeed,
29 Sep 2006:
Biopharmaceuticals, Oncology, FDA[Genentech, Biogen Idec, Rituxan, Rituximab, non-Hodgkin's lymphoma]
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
HSMN NewsFeed,
26 Sep 2006:
Biopharmaceuticals, Mergers & Acquisitions[Millennium Pharmaceuticals, AnorMED]
ProNAi Announces Executive Team Buildup, Names New CEO and Top Development Management
HSMN NewsFeed,
26 Sep 2006:
Biopharmaceuticals, Personnel[ProNAi Therapeutics]
Cell Therapeutics Inc. Announces Worldwide License and Co-Development Agreement for Development and Commercialization of XYOTAX(TM), an Investigational Agent for Treatment of Women with Non-small Cell Lung Cancer and Other Cancers
HSMN NewsFeed,
18 Sep 2006:
Biopharmaceuticals, Oncology, Licensing[Cell Therapeutics, Novartis, XYOTAX, non-small cell lung cancer]
AnorMED Board recommends shareholders reject hostile Genzyme offer and not tender shares
HSMN NewsFeed,
5 Sep 2006:
Biopharmacetuicals, Mergers & Acquisitions[AnorMED, Genzyme]
Genzyme to Initiate Tender Offer to Acquire AnorMED, Inc.
HSMN NewsFeed,
30 Aug 2006:
Biopharmaceuticals, Mergers & Acquisitions[Genzyme, AnorMED]
Genentech and Biogen Idec Announce Positive Results From a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
HSMN NewsFeed,
28 Aug 2006:
Biopharmaceuticals, Neurology[Genentech, Biogen Idec, Rituxan, Rituximab, multiple sclerosis]
FDA Grants Priority Review to VELCADE(R) (Bortezomib) for Injection for Treatment of Relapsed Mantle Cell Lymphoma
HSMN NewsFeed,
9 Aug 2006:
Biopharmaceuticals, Oncology, FDA[Millennium Pharmaceuticals, VELCADE, mantle cell lymphoma]
Cell Therapeutics, Inc. (CTI) Announces Encouraging Pixantrone Phase III Interim Data
HSMN NewsFeed,
8 Aug 2006:
Biopharmaceuticals, Onocology[Cell Therapeutics, non-Hodgkin's lymphoma, pixantrone]
Allos Therapeutics Receives Special Protocol Assessment for Pivotal Phase 2 Study of the Company's Novel Antifolate PDX in Patients with Peripheral T-cell Lymphoma
HSMN NewsFeed,
2 Aug 2006:
Biopharmaceuticals, Oncology[Allos Therapeutics, antifolate PDX, pralatrexate, peripheral T-cell lymphoma]
Data Safety Monitoring Board Recommends Continuation of MyVax(R) Personalized Immunotherapy Phase 3 Trial After Second Interim Analysis
HSMN NewsFeed,
27 Jul 2006:
Biopharmaceuticals, Oncology[Genitope, MyVax, personalized immunotherapy]
FDA Grants Orphan Drug Designation to Allos Therapeutics' Novel Antifolate PDX for the Treatment of T-cell Lymphoma
HSMN NewsFeed,
26 Jul 2006:
Biopharmaceuticals, FDA, Oncology[Allos Therapeutics, orphan drug designation, PDX, pralatrexate, T-cell lymphoma]
AnorMED completes enrollment in Phase III trial for MOZOBIL in stem cell transplant in multiple myeloma
HSMN NewsFeed,
10 Jul 2006:
Biopharmaceuticals, Oncology[AnorMED, MOZOBIL, multiple myeloma, non-Hodgkin's lymphoma]
Favrille Publishes Data From Phase 2 Clinical Trial Demonstrating Biologic Activity of Lead Product Candidate FavId in Indolent Non-Hodgkin's Lymphoma
HSMN NewsFeed,
5 Jul 2006:
Biopharmaceuticals, Oncology[Favrille, FavId, non-Hodgkin's lymphoma]
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
HSMN NewsFeed,
22 Jun 2006:
Biopharmaceuticals[Genentech, Rituxan, Rituximab, Rheumatoid Arthritis]
PRAECIS PHARMACEUTICALS INCORPORATED Announces Cessation of Plenaxis(R) Disposition Efforts
HSMN NewsFeed,
20 Jun 2006:
Biopharmaceuticals[PRAECIS PHARMACEUTICALS, Plenaxis]
Favrille Announces FDA Allowance of Investigational New Drug Application for FAV-201, a Patient-Specific Immunotherapy for T-Cell Lymphoma
HSMN NewsFeed,
15 Jun 2006:
Biopharmaceuticals, Oncology, FDA[Favrille, FAV-201]
Retrospective Analysis of Allos Therapeutics' Phase 3 REACH Study Finds Positive Correlation between Patient Outcomes and EFAPROXYN(TM) (efaproxiral) Exposure in Patients with Brain Metastases from Breast and Non-Small Cell Lung Cancers
HSMN NewsFeed,
14 Jun 2006:
Biopharmaceuticals, Oncology[Allos Therapeutics, EFAPROXYN, efaproxiral]
FDA Grants Fast Track Status to MyVax(R) Personalized Immunotherapy for Follicular Non-Hodgkin's Lymphoma
HSMN NewsFeed,
13 Jun 2006:
Biopharmaceuticals, Oncology, FDA[Genitope, MyVax, Fast Track designation, follicular non-Hodgkin's Lymphoma]
ZOLINZA(TM), Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), to Receive Priority Review from U.S. Food and Drug Administration
HSMN NewsFeed,
7 Jun 2006:
Biopharmaceuticals, Oncology, FDA[Merck, ZOLINZA, vorinostat, SAHA , T-cell-lymphoma]
Allos Therapeutics Appoints James V. Caruso as Chief Commercial Officer
HSMN NewsFeed,
5 Jun 2006:
Biopharmaceuticals, Personnel[Allos Therapeutics]
AnorMED announces departure of Vice President Communications
HSMN NewsFeed,
2 Jun 2006:
Biopharmaceuticals, Personnel[AnorMED]
Association Between Molecular Remission and Disease-Free Survival in Non-Hodgkins Lymphoma at Over Nine Years Follow-Up To Be Presented
HSMN NewsFeed,
24 May 2006:
Biopharmaceuticals, Oncology[Accentia BioPharmaceuticals, BiovaxID, Non-Hodgkins Lymphoma]
Cabrellis Pharmaceuticals Corporation Announces Corporate Launch and Founding Management Team
HSMN NewsFeed,
17 May 2006:
Biopharmaceuticals, Oncology, Personnel[Cabrellis Pharmaceuticals, Conforma Therapeutics, amrubicin]
FDA Gives Permission to Use Very Sensitive Molecular Evidence of Cancer in BiovaxID Pivotal Phase 3 Clinical Trial
HSMN NewsFeed,
16 May 2006:
Biopharmaceuticals, Oncology, FDA[Biovest, Accentia Biopharmaceuticals, BiovaxID, non-Hodgkin's lymphoma]
Genitope Corporation Appoints Dr. Mary Rybak Vice President of Medical Affairs
HSMN NewsFeed,
16 May 2006:
Biopharmaceuticals, Personnel[Genitope]
Bioenvision and Mayne Pharma Announce Marketing and Distribution Agreement for Evoltra(R)
HSMN NewsFeed,
16 May 2006:
Biopharmaceuticals, Oncology, Distribution[Bioenvision, Mayne Pharma, Evoltra, clofarabine]
FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM)
HSMN NewsFeed,
11 May 2006:
Biopharmaceuticals, Oncology, FDA[Accentia Biopharmaceuticals, BiovaxID, non-Hodgkin's lymphoma]
Biovest's AutovaxID(TM) Cleared for Commercial Sale
HSMN NewsFeed,
10 May 2006:
Biopharmaceuticals, Devices, FDA[Accentia Biopharmaceuticals, Biovest, AutovaxID, personalized medicine]
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
HSMN NewsFeed,
10 May 2006:
Biopharmaceuticals, Licensing[Immunomedics, UCB , epratuzumab, Systemic Lupus Erythematosus]
Accentia Biopharmaceuticals Receives FDA Approval for Three Unique Dosage Combination Pain Product ANDAs
HSMN NewsFeed,
8 May 2006:
Biopharmaceuticals, FDA[Accentia Biopharmaceuticals, Xodol, hydrocodone]
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
HSMN NewsFeed,
8 May 2006:
Biopharmaceuticals, Oncology, Licensing[Hana Biosciences, Inex Pharmaceuticals, Marqibo, vincristine, Vinorelbine]
Micromet and CancerVax Complete Merger To Form Micromet, Inc.
HSMN NewsFeed,
5 May 2006:
Biopharmaceuticals, Mergers & Acquisitions[Micromet , CancerVax]
Biovest International Announces Addition to Senior Management Team
HSMN NewsFeed,
4 May 2006:
Biopharmaceuticals, Personnel[Biovest]
CancerVax Stockholders Approve Merger With Micromet
HSMN NewsFeed,
3 May 2006:
Biopharmaceuticals, Oncology, Mergers & Acquisitions[CancerVax, Micromet AG]
PRAECIS PHARMACEUTICALS INCORPORATED Appoints Prem Das as Senior Vice President, Technology Partnerships
HSMN NewsFeed,
20 Apr 2006:
Biopharmaceuticals, Personnel[PRAECIS PHARMACEUTICALS]
National Survey of U.S. Otolaryngologists First to Measure Dissatisfaction with Current Treatments for Chronic Sinusitis
HSMN NewsFeed,
20 Apr 2006:
Biopharmaceuticals[Accentia Biopharmaceuticals, chronic sinusitis, SinuNase]
Millennium and Johnson & Johnson Pharmaceutical Research and Development Initiate Phase III Clinical Trial with VELCADE(R) (bortezomib) for Injection in Follicular Non-Hodgkin's Lymphoma
HSMN NewsFeed,
18 Apr 2006:
Biopharmaceuticals, Oncology[Millennium Pharmaceuticals, Johnson & Johnson, VELCADE]
FDA Grants Accentia Biopharmaceuticals Fast Track Status for SinuNase(TM)
HSMN NewsFeed,
12 Apr 2006:
Biopharmaceuticals, FDA[Accentia Biopharmaceuticals, SinuNase, fast track designation]
Bioenvision's Evoltra(R) Achieves High Response Rates in Adult AML
HSMN NewsFeed,
5 Apr 2006:
Biopharmaceuticals, Oncology[Bioenvision, acute myeloid leukemia , Evoltra, clofarabine]
Cephalon Oncology Compound Lestaurtinib (CEP-701) Granted Orphan Drug Designation for Acute Myeloid Leukemia
HSMN NewsFeed,
4 Apr 2006:
Biopharmaceuticals, FDA, Oncology[Cephalon, orphan drug designation, lestaurtinib, CEP-701, acute myeloid leukemia]
Enzon Initiates Clinical Program for ONCASPAR(R)
HSMN NewsFeed,
3 Apr 2006:
Biopharmaceuticals, Oncology, FDA[Enzon Pharmaceuticals, ONCASPAR, pegaspargase, Non-Hodgkin's Lymphoma]
Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan(R) in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin's Lymphoma
HSMN NewsFeed,
30 Mar 2006:
Biopharmaceuticals, Oncology, FDA[Genentech, Biogen Idec, Rituxan, rituximab, non-Hodgkin's lymphoma]
Pixantrone Combination Regimen Produces High Rates of Complete Remission for Patients With Aggressive NHL Who Fail CHOP Therapy
HSMN NewsFeed,
22 Mar 2006:
Biopharmaceuticals, Oncology[Cell Therapeutics, pixantrone, non-Hodgkin's lymphoma]
Hana Biosciences to License Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
HSMN NewsFeed,
17 Mar 2006:
Biopharmaceuticals, Oncology, Licensing[Hana Biosciences, Inex Pharmaceuticals, Marqibo]
Inex Pharmaceuticals Licenses Three Targeted Chemotherapy Products to Hana Biosciences
HSMN NewsFeed,
17 Mar 2006:
Biopharmaceuticals, Oncology, Licensing[Inex Pharmaceuticals, Hana Biosciences, Marqibo]
PRAECIS PHARMACEUTICALS INCORPORATED Presents Update on its DirectSelect(TM) Technology
HSMN NewsFeed,
15 Mar 2006:
Biopharmaceuticals[PRAECIS PHARMACEUTICALS, DirectSelect]
Allos Therapeutics Appoints Paul L. Berns as President and CEO
HSMN NewsFeed,
10 Mar 2006:
Biopharmaceuticals, Personnel[Allos Therapeutics]
Lilly Launches Phase III Trial of Targeted Cancer Agent
HSMN NewsFeed,
9 Mar 2006:
Biopharmaceuticals, Oncology[Eli Lilly, Enzastaurin, glioblastoma multiforme]
FDA Approves Rituxan(R) - The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
HSMN NewsFeed,
28 Feb 2006:
Biopharmaceuticals, FDA[Genentech, Biogen Idec, Rituxan, Rituximab, methotrexate, rheumatoid arthritis]
PRAECIS PHARMACEUTICALS INCORPORATED Presents Update on its DirectSelect(TM) Technology
HSMN NewsFeed,
22 Feb 2006:
Biopharmaceuticals[PRAECIS PHARMACEUTICALS, DirectSelect]
Biovest International Submits Amendment Request to FDA for Use of Molecular Remission Data in the Ongoing Pivotal Phase 3 Study to Support Accelerated, Conditional Approval of BiovaxID (TM), a Personalized Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
HSMN NewsFeed,
22 Feb 2006:
Biopharmaceuticals, Oncology, FDA[Accentia Biopharmaceuticals, Biovest, BiovaxID, Non-Hodgkin's Lymphoma]
SinuNase(TM) IND On Track
HSMN NewsFeed,
14 Feb 2006:
Biopharmaceuticals[Accentia Biopharmaceuticals, SinuNase, chronic sinusitis]
European Regulatory Committee Recommends Orphan Drug Status for GPC Biotech's Anticancer Monoclonal Antibody 1D09C3 for Multiple Myeloma
HSMN NewsFeed,
14 Feb 2006:
Biopharmaceuticals, Oncology, Regulatory[GPC Biotech, D09C3, multiple myeloma, orphan drug designation]
CuraGen and TopoTarget Initiate Phase II Clinical Trial of PXD101 for T-Cell Lymphoma
HSMN NewsFeed,
1 Feb 2006:
Biopharmaceuticals, Oncology[CuraGen, TopoTarget, PXD101, non-Hodgkin's lymphomas]
Favrille Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial of FavId for Follicular B-Cell Non-Hodgkin's Lymphoma
HSMN NewsFeed,
30 Jan 2006:
Biopharmaceuticals, Oncology[Favrille, FavId, non-Hodgkin's lymphoma]
Orphan Drug Designation Granted by European Commission for Anticancer Monoclonal Antibody 1D09C3 for Chronic Lymphocytic Leukemia
HSMN NewsFeed,
27 Jan 2006:
Biopharmaceuticals, Oncology, Regulatory[GPC Biotech, orphan drug designation, 1D09C3, chronic lymphocytic leukemia]
Trubion Names Michelle Burris Senior Vice President and CFO
HSMN NewsFeed,
25 Jan 2006:
Biopharmaceuticals, Personnel[Trubion Pharmaceuticals]
Subcutaneous Genasense(R) Trial Initiated in Patients with Solid Tumors
HSMN NewsFeed,
24 Jan 2006:
Biopharmaceuticals, Oncology[Genta , Genasense, oblimersen]
BioCryst Receives FDA Fast Track Designation for Peramivir
HSMN NewsFeed,
17 Jan 2006:
Biopharmaceuticals, FDA[BioCryst Pharmaceuticals, fast track designation, peramivir, influenza]
Allos Therapeutics Announces CEO Succession Plans
HSMN NewsFeed,
16 Jan 2006:
Biopharmaceuticals, Personnel[Allos Therapeutics]
Favrille Receives FDA Fast Track Designation for FavId, Lead Product Candidate for Follicular B-Cell Non-Hodgkin's Lymphoma
HSMN NewsFeed,
12 Jan 2006:
Biopharmaceuticals, Oncology, FDA[Favrille, FavId, fast track designation, non-Hodgkin's lymphoma]
Biovest International Announces Addition to Senior Management Team
HSMN NewsFeed,
4 Jan 2006:
Biopharmaceuticals, Personnel[Biovest International]
Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases Originating From Breast Cancer
HSMN NewsFeed,
3 Jan 2006:
Biopharmaceuticals, Oncology[Allos Therapeutics, EFAPROXYN, efaproxiral]
Additional items found: The Network Archive contains
315 additional itemsNon-Hodgkin's Lymphoma
Public
Feeds 
Full text >>
